Verastem (NASDAQ:VSTM) hosts its annual research and development day. Highlights: VSTM says it plans to have "three candidates in six clinical trials ongoing in parallel by the end of 2013"; Phase 1 portion of Phase 1/1b VS-6063 study is complete; "a significant decrease in the CA-125 biomarker in several patients" was observed; treatment is well tolerated in combination with paclitaxel, opening the door for exploring "this combination in a wide range of cancers."
Verastem (NASDAQ:VSTM) hosts its annual research and development day. Highlights: VSTM says it...
Recommended For You
More Trending News
About VSTM Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| VSTM | - | - |
| Verastem, Inc. | ||